SSY GROUP(02005): Obtained the drug production registration approval for 0.2g indobufen tablets.

SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for indobufen tablets (0.2g), which belong to the third category of chemical drugs and are considered to have passed consistency evaluation. Indobufen tablets are mainly used to treat ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as to prevent thrombosis during hemodialysis.